Scottish Medicines Consortium (SMC) has recommended Fabhalta® (iptacopan) as monotherapy for adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia and used under the ...

Explore opportunities with Novartis below.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

At Novartis, we have a strong commitment to sustainable development. As a global organization, we recognize the opportunity to drive positive social change. We are on a continuous journey to channel ...

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...

A Non-interventional multiCenter Observational Study to Evaluate tHe Effectiveness and Patient-Reported Outcomes of Ofatumumab (Kesimpta®) in patieNts With Relapsing Multiple sclerOsis Treated in ...

Un 62% de las entidades de pacientes coinciden en que la profesionalización de sus organizaciones es uno de los principales retos a los que se enfrentan. Un hecho que impacta, según estas entidades, ...